Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) - guidance (TA568)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
13 March 2019

Abstract

NICE is unable to make a recommendation about the use in the NHS of abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because no evidence submission was received from Bristol–Myers Squibb. We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance